Objective: To examine the association between XPD and hOGG1 polymorphisms and prostate cancer (PCa) susceptibility. Methods: A comprehensive search was conducted to identify all case-control studies on the relationship between XPD and hOGG1 polymorphisms and PCa risk. Odds ratios (ORs) were used to investigate the strength of the associations. Results: A total of 15 case-control studies including 5,765 cases and 6,270 controls were eligible for the meta-analyses. For XPD Asp312Asn, no evidence indicated that individuals carrying 312Asn had an increased risk of PCa. In subgroup analyses, Asp312Asn polymorphism was associated with PCa risk in Asian populations [OR = 2.09 and 95% CI = 1.39–3.14 for Asn/Asn vs. Asp/Asp; OR = 1.49 and 95% CI = 1.12–1.98 for (Asn/Asn+Asn/Asp) vs. Asp/Asp]. For XPD Lys751Gln, the individuals with 751Gln did not have increased PCa risk compared with those with 751Arg, and no association was found in the subgroup analyses. For hOGG1 Ser326Cys, no significant association between the polymorphism and PCa risk was observed in the overall analysis. However, Ser326Cys was significantly associated with PCa risk under homologous contrast in Caucasians and Asians. Conclusions: XPD Asp312Asn polymorphism is associated with PCa risk in Asians and hOGG1 Ser326Cys polymorphism is associated with PCa risk in Caucasians and Asians.

Keywords:
XPD, hOGG1, Polymorphism, Prostatic neoplasms, Susceptibility, Meta-analysis
1.
Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30.
2.
Shields PG, Harris CC: Molecular epidemiology and the genetics of environmental cancer. JAMA 1991;266:681–687.
3.
De Marzo AM, Marchi VL, Epstein JI, et al: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985–1992.
4.
Khandrika L, Kumar B, Koul S, et al: Oxidative stress in prostate cancer. Cancer Lett 2009;282:125–136.
5.
Sancar A, Tang MS: Nucleotide excision repair. Photochem Photobiol 1993;57:905–921.
6.
Goode EL, Ulrich CM, Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513–1530.
7.
Friedberg EC: How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001;1:22–33.
8.
Agalliu I, Kwon EM, Salinas CA, et al: Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study. Cancer Causes Control 2010;21:289–300.
9.
Dhillon VS, Yeoh E, Fenech M: DNA repair gene polymorphisms and prostate cancer risk in South Australia – results of a pilot study. Urol Oncol 2011;29:641–646.
10.
Nock NL, Cicek MS, Li L, et al: Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 2006;27:1842–1848.
11.
Mandal RK, Gangwar R, Mandhani A, et al: DNA repair gene X-ray repair cross-complementing group 1 and xeroderma pigmentosum group D polymorphisms and risk of prostate cancer: a study from North India. DNA Cell Biol 2010;29:183–190.
12.
Lavender NA, Komolafe OO, Benford M, et al: No association between variant DNA repair genes and prostate cancer risk among men of African descent. Prostate 2010;70:113–119.
13.
Handoll HH: Systematic reviews on rehabilitation interventions. Arch Phys Med Rehabil 2006;87:875.
14.
Bau DT, Wu HC, Chiu CF, et al: Association of XPD polymorphisms with prostate cancer in Taiwanese patients. Anticancer Res 2007;27:2893–2896.
15.
Rybicki BA, Conti DV, Moreira A, et al: DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:23–29.
16.
Gao R, Price DK, Dahut WL, et al: Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer. Cancer Biol Ther 2010;10:13–18.
17.
Ritchey JD, Huang WY, Chokkalingam AP, et al: Genetic variants of DNA repair genes and prostate cancer: a population-based study. Cancer Epidemiol Biomarkers Prev 2005;14:1703–1709.
18.
Yun SJ, Ha YS, Chae Y, et al: The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population. Ann Oncol 2012;23:401–405.
19.
Zhang J, Dhakal IB, Greene G, et al: Polymorphisms in hOGG1 and XRCC1 and risk of prostate cancer: effects modified by plasma antioxidants. Urology 2010;75:779–785.
20.
Nam RK, Zhang WW, Jewett MA, et al: The use of genetic markers to determine risk for prostate cancer at prostate biopsy. Clin Cancer Res 2005;11:8391–8397.
21.
Chen L, Elahi A, Pow-Sang J, et al: Association between polymorphism of human oxoguanine glycosylase 1 and risk of prostate cancer. J Urol 2003;170:2471–2474.
22.
Xu J, Zheng SL, Turner A, et al: Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res 2002;62:2253–2257.
23.
Zhou C: A Case-control study on the association between single nucleotide polymorphism (SNP) of ERCCZ/XPD and hOGGI and prostate cancer susceptibility. Hangzhou, Zhejiang University, 2011.
24.
Kohno T, Shinmura K, Tosaka M, et al: Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene 1998;16:3219–3225.
25.
Kopec JA, Esdaile JM: Bias in case-control studies: a review. J Epidemiol Community Health 1990;44:179–186.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.